{"id":9290,"date":"2020-05-06T13:02:33","date_gmt":"2020-05-06T11:02:33","guid":{"rendered":"https:\/\/www.resist-cluster.de\/?page_id=9290"},"modified":"2025-01-07T12:55:37","modified_gmt":"2025-01-07T11:55:37","slug":"prof-dr-dirk-schlueter","status":"publish","type":"page","link":"https:\/\/www.resist-cluster.de\/en\/about-us\/research-team-2\/prof-dr-dirk-schlueter\/","title":{"rendered":"Prof. Dr. Dirk Schl\u00fcter"},"content":{"rendered":"

<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/a><\/span><\/div>

Prof. Dr. Dirk Schl\u00fcter participates in\u00a0RESIST research project B12.<\/p>\n<\/div>

<\/div><\/div><\/div>

\n\n\n
<\/i><\/td>\nMy Research Interest in RESIST<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/h1><\/div>

Our research focus in RESIST is the characterization of the function of deubiquitinating enzymes (DUBs) in human bacterial infection, the evaluation of DUBs as novel drug targets and the development of small molecular compounds that selectively inhibit individual DUBs. The long-term goal is to contribute to the validation of new treatment strategies for bacterial infections, which target bacteria by antibiotic and simultaneously improve the anti-bacterial immune response by treatment with immunostimulatory DUB inhibitors. In the last years, we have shown that the DUBs CYLD, TNFAIP3 (A20) and OTUB1 are critical regulators of immune responses in experimental infectious and autoimmune disorders.<\/p>\n

Built on this expertise and data, we will use innovative mouse models to carry out the structure\/function analyses of DUBs in experimental Listeria monocytogenes<\/em> and Staphylococcus aureus<\/em> infections. We combine these infection models with studies on the function of DUBs and S. aureus<\/em> in atopic dermatitis, since colonization of the skin with S. aureus<\/em> aggravates atopic dermatitis and S. aureus<\/em> frequently causes infections in AD patients (collaboration T. Werfel, L. R\u00f6sner; project A3, A4, B5, RESIST-Cohort). Our recent data show that individual DUBs are increasingly expressed in AD and attenuate the control of S. aureus by macrophages. Based on these data, we will develop DUB inhibitors that target specific domains of DUBs previously identified as relevant and test them in the aforementioned models.<\/p>\n<\/div>

<\/div>
<\/div>
<\/div>
<\/i><\/span>Contact<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/path><\/svg><\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div>

Prof. Schl\u00fcter about his scientific work<\/h1><\/div>